市場調查報告書

生物標記的全球市場分析、預測:2019-2026年

Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostic, Drug Development, Personalized Medicine), By Disease, And Segment Forecasts, 2019 - 2026

出版商 Grand View Research, Inc. 商品編碼 823401
出版日期 內容資訊 英文 103 Pages
商品交期: 2-3個工作天內
價格
Back to Top
生物標記的全球市場分析、預測:2019-2026年 Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostic, Drug Development, Personalized Medicine), By Disease, And Segment Forecasts, 2019 - 2026
出版日期: 2019年04月04日內容資訊: 英文 103 Pages
簡介

全球生物標記的市場在預測期間內預計將以14.2%的年複合成長率 (CAGR) 發展,到2026年超過1180億美元的規模。技術發展,高的消費者意識,R&D資金的擴大等要素促進該市場的成長。

本報告提供全球生物標記的市場調查,市場及產品概要,價值鏈,相關法律,市場成長的各種影響因素分析,各生物標記類型、用途、疾病區分、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等資訊彙整。

第1章 調查手法、調查範圍

第2章 摘要整理

第3章 市場可變因素、趨勢、展望

  • 市場展望
  • 普及、成長製圖
  • 價值鏈分析
  • 法律規章上架構
  • 市場動態
    • 成長推動因素分析
    • 阻礙成長要素分析
  • 市場分析工具
    • 波特分析
    • PESTEL分析
    • 主要的聯盟、契約分析

第4章 競爭分析

  • 近幾年的發展、影響分析:各主要進入業者
  • 企業的分類
  • 供應商環境
  • 上市公司
  • 非上市公司

第5章 市場估計、趨勢分析:各生物標記類型

  • 定義、調查範圍
  • 市場佔有率成果、預測
  • 市場預測、趨勢分析
    • 安全性
    • 有效性
    • 驗證

第6章 市場估計、趨勢分析:各用途

  • 定義、調查範圍
  • 市場佔有率成果、預測
  • 市場預測、趨勢分析
    • 診斷
    • 藥物開發
    • 個人化醫療

第7章 市場估計、趨勢分析:各疾病種類

  • 定義、調查範圍
  • 市場佔有率成果、預測
  • 市場預測、趨勢分析:各疾病區分、生物標記類型
    • 癌症
    • 心血管疾病
    • 神經疾病
    • 免疫疾病
    • 其他

第8章 市場估計、趨勢分析:各地區、主要國家

  • 各地區趨勢
  • 主要企業
  • SWOT分析
  • 市場規模的變化、預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲

第9章 競爭環境

  • 策略性架構
  • 熱圖分析
  • F-Hoffman La Roche Ltd.
  • Abbott
  • Epigenomics AG
  • General Electric Company
  • Johnson & Johnson
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare Private Limited
  • Qiagen
目錄
Product Code: 978-1-68038-979-1

The global biomarkers market size is expected to reach over USD 118 billion by 2026, according to a new study by Grand View Research Inc. It is projected to expand at a CAGR of 14.2% during the forecast period. Technological advancements, high consumer awareness, and increasing funds for research and development (R&D) activities are collectively propelling the market growth.

Drug discovery was estimated to be one of the highest revenue generating segments of the market. Pharmaceutical companies are undertaking extensive R&D initiatives to develop targeted therapeutics. Coordinated research efforts on biomarker development is a rising trend among commercial R&D organizations, academic research institutions, federal government biomedical regulatory and research agencies, and nonprofitable health foundations.

North America led the biomarker market in 2018, driven by high disease prevalence, proactive governmnet initiatives, and substantial demand for personalized medicines. North America is anticipated to retain its leading position throughout the forecast period. Asia Pacific is expected to witness the fastest regional growth, spearheaded by India.

Some key players operating in the biomarkers market include F. Hoffmann-La Roche Ltd.; Abbott.; Epigenomics AG; Agilent Technologies, Inc.; Johnson & Johnson Services, Inc; Siemens Healthcare Private Limited; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Qiagen. Key players are developing novel kits and therapies or drugs to target population in the areas with high unmet clinical needs.

Further key findings from the study suggest:

Safety biomarkers held the largest market share of over 42% in 2018 due to reduction in drug attrition and increasing awareness of routine healthcare checkups

Validation biomarkers is estimated to be one of the fastest growing segments

Personalized medicine is estimated to grow at a CAGR of 15.0% over the forecast period owing to growing consumer awareness

Cancer held the largest market share in 2018, driven by an increase in global prevalence of cancer and the presence of a strong pipeline of drugs

Cardiovascular diseases is projected to be the fastest growing segment throughout the forecast period, supported by sedentary lifestyles and growing obese population.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third party perspectives
    • 1.3.4. Primary research
  • 1.4. Information Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

  • 3.1. Biomarkers Market Lineage outlook
    • 3.1.1. Clinical diagnostics market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Regulatory Framework
    • 3.3.1. Reimbursement framework
    • 3.3.2. Standards & compliances
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing prevalence of chronic diseases
      • 3.4.1.2. Technological advancements
      • 3.4.1.3. Funding for biomrkers
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. Reimbursement policies
  • 3.5. Biomarkers Market Analysis Tools
    • 3.5.1. Industry analysis - Porter's
      • 3.5.1.1. Supplier power: (High due to large number of manufacturers)
      • 3.5.1.2. Buyer power: (Moderate due tolong-term contracts with manufacturers)
      • 3.5.1.3. Substitution threat: (Moderate due to no/less external substitutes)
      • 3.5.1.4. Threat from new entrant: (Moderate due to limited number of new players)
      • 3.5.1.5. Competitive rivalry: (High due to mergers & acquisitions by major players)
    • 3.5.2. PESTEL analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Environmental landscape
      • 3.5.2.3. Social landscape
      • 3.5.2.4. Technology landscape
      • 3.5.2.5. Legal landscape
    • 3.5.3. major deals & strategic alliances analysis
      • 3.5.3.1. Joint ventures
      • 3.5.3.2. Mergers & acquisitions
      • 3.5.3.3. Licensing & partnership
      • 3.5.3.4. Technology collaborations
      • 3.5.3.5. Strategic divestments

Chapter 4. Biomarkers Market - Competitive Analysis

  • 4.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 4.3. Vendor Landscape
    • 4.3.1. List of key distributors and channel partners
    • 4.3.2. Key company market share analysis, 2018
  • 4.4. Public Companies
    • 4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 4.4.2. Company Market Share
    • 4.4.3. Competitive Dashboard Analysis
    • 4.4.4. Market Differentiators
    • 4.4.5. Synergy Analysis: Major Deals & Strategic Alliances
  • 4.5. Private Companies
    • 4.5.1. List of key emerging companies
    • 4.5.2. Regional network map
    • 4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Biomarkers Market: Type Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Type Market Share Analysis, 2018 & 2026
  • 5.3. Biomarkers Market, by Type, 2014 to 2026
  • 5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
    • 5.4.1. Safety
      • 5.4.1.1 Safety market, 2014 - 2026 (USD Million)
    • 5.4.2. Efficacy
      • 5.4.2.1 Efficacy market, 2014 - 2026 (USD Million)
    • 5.4.3. Validation
      • 5.4.3.1 Validation market, 2014 - 2026 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Definitions & Scope
  • 6.2. Application Market Share Analysis, 2018 & 2026
  • 6.3. Biomarkers Market, by Application, 2014 to 2026
  • 6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
    • 6.4.1. Diagnostics
      • 6.4.1.1 Diagnostics market, 2014 - 2026 (USD Million)
    • 6.4.2. Drug development
      • 6.4.2.1 Drug development market, 2014 - 2026 (USD Million)
    • 6.4.3. Personalized medicine
      • 6.4.3.1 Personalized medicine market, 2014 - 2026 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

  • 7.1. Definitions & Scope
  • 7.2. Disease Market Share Analysis, 2018 & 2027
  • 7.3. Biomarkers Market, by Disease, 2014 to 2027
  • 7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2027 for the following,
    • 7.4.1. Cancer
      • 7.4.1.1 Cancer market, 2014-2027 (USD Million)
    • 7.4.2. Cardiovascular disease
      • 7.4.2.1 Cardiovascular disease market, 2014-2027 (USD Million)
    • 7.4.3. Neurological disease
      • 7.4.3.1 Neurological disease market, 2014-2027 (USD Million)
    • 7.4.4. Immunological disease
      • 7.4.4.1 Immunological disease market, 2014-2027 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1 Others market, 2014-2027 (USD Million)
  • 7.5. Disease Market, by Type, 2014 - 2026:
    • 7.5.1. Cancer
      • 7.5.1.1 Safety
      • 7.5.1.1.1 Cancer biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.1.2 Efficacy
      • 7.5.1.1.2 Cancer biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.1.3 Validation
      • 7.5.1.1.3 Cancer biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.2. Cardiovascular diseases
      • 7.5.2.1 Safety
      • 7.5.2.1.1 Cardiovascular biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.2.2 Efficacy
      • 7.5.2.1.2 Cardiovascular biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.2.3 Validation
      • 7.5.2.1.3 Cardiovascular biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.3. Neurological disease
      • 7.5.3.1 Safety
      • 7.5.3.1.1 Neurological biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.3.2 Efficacy
      • 7.5.3.1.2 Neurological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.3.3 Validation
      • 7.5.3.1.3 Neurological biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.4. Imunological disease
      • 7.5.4.1 Safety
      • 7.5.4.1.1 Imunological biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.4.2 Efficacy
      • 7.5.4.1.2 Imunological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.4.3 Validation
      • 7.5.4.1.3 Imunological biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.5. Others
      • 7.5.5.1 Safety
      • 7.5.5.1.1 Other biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.5.2 Efficacy
      • 7.5.5.1.2 Other biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.5.3 Validation
      • 7.5.5.1.3 Other biomarkers market, by validation, 2014 - 2026 (USD Million)

Chapter 8 Biomarkers Market: Regional Estimates & Trend Analysis, by Type, Application, & Disease

  • 8.1 Biomarkers Market: Regional Movement Analysis, 2018 & 2026
  • 8.2 Biomarkers Market: Leading Players, 2018:
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4 North America
    • 8.4.1 North America biomarkers market, 2014 - 2026 (USD Million)
    • 8.4.2 U.S.
      • 8.4.2.1 U.S. biomarkers market, 2014 - 2026 (USD Million)
    • 8.4.3 Canada
      • 8.4.3.1 Canada biomarkers market, 2014 - 2026 (USD Million)
  • 8.5. Europe
    • 8.5.1 Europe biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.2 UK
      • 8.5.2.1 UK biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.3 Germany
      • 8.5.3.1 Germany biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.4 Spain
      • 8.5.4.1 Spain biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.5 France
      • 8.5.5.1 France biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.6 Italy
      • 8.5.6.1 Italy biomarkers market, 2014 - 2026 (USD Million)
  • 8.6 Asia Pacific
    • 8.6.1 Asia Pacific biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.2 Japan
      • 8.6.2.1 Japan biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.3 India
      • 8.6.3.1 India biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.4 South Korea
      • 8.6.4.1 South Korea biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.5 China
      • 8.6.5.1 China biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.6 Australia
      • 8.6.6.1 Australia biomarkers market, 2014 - 2026 (USD Million)
  • 8.7 Latin America
    • 8.7.1 Latin America biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.2 Brazil
      • 8.7.2.1 Brazil biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.3 Mexico
      • 8.7.3.1 Mexico biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.4 Argentina
      • 8.7.4.1 Argentina biomarkers market, 2014 - 2026 (USD Million)
  • 8.8 MEA
    • 8.8.1 MEA biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.2 South Africa
      • 8.8.2.1 South Africa biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.3 United Arab Emirates
      • 8.8.3.1 United Arab Emirates biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.4 Saudi Arabia
      • 8.8.4.1 Saudi Arabia biomarkers market, 2014 - 2026 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Heat Map Analysis of Private Companies
    • 9.2.1 Company size
    • 9.2.2 Distribution network
    • 9.2.3 Product portfolio
    • 9.2.4 Segment coverage
    • 9.2.5 Geographic presence
    • 9.2.6 Collaborations
    • 9.2.7 Conclusion
  • 9.3 F-Hoffman La Roche Ltd.
    • 9.3.1 Company overview
    • 9.3.2 Financial performance
    • 9.3.3 Product benchmarking
    • 9.3.4 Strategic initiatives
  • 9.4 Abbott
    • 9.4.1 Company overview
    • 9.4.2 Financial performance
    • 9.4.3 Product benchmarking
    • 9.4.4 Strategic initiatives
  • 9.5 Epigenomics AG
    • 9.5.1 Company overview
    • 9.5.2 Financial performance
    • 9.5.3 Product benchmarking
    • 9.5.4 Strategic initiatives
  • 9.6 General Electric Company
    • 9.6.1 Company overview
    • 9.6.2 Financial performance
    • 9.6.3 Product benchmarking
    • 9.6.4 Strategic initiatives
  • 9.7 Johnson & Johnson
    • 9.7.1 Company overview
    • 9.7.2 Financial performance
    • 9.7.3 Product benchmarking
    • 9.7.4 Strategic initiatives
  • 9.8 Thermo Fisher Scientific, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Financial performance
    • 9.8.3 Product benchmarking
    • 9.8.4 Strategic initiatives
  • 9.9 Bio-Rad Laboratories, Inc.
    • 9.9.1 Company overview
    • 9.9.2 Financial performance
    • 9.9.3 Product benchmarking
    • 9.9.4 Strategic initiatives
  • 9.10 Siemens Healthcare Private Limited
    • 9.10.1 Company overview
    • 9.10.1 Financila performance
    • 9.10.2 Product benchmarking
    • 9.10.3 Strategic initiatives
  • 9.11 Qiagen
    • 9.11.1 Company Overview
    • 9.11.2 Financial performance
    • 9.11.3 Product benchmarking
    • 9.11.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 3 North America biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 4 North America biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 5 North America biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 6 U.S. biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 7 U.S. biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 8 U.S. biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 9 Canada biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 10 Canada biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 11 Canada biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 12 Europe biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 13 Europe biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 14 Europe biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 15 Europe biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 16 UK biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 17 UK biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 18 UK biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 19 Germany biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 20 Germany biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 21 Germany biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 13 Spain biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 14 Spain biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 15 Spain biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 16 France biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 17 France biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 18 Francebiomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 19 Italy biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 20 Italy biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 21 Italy biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 22 Asia Pacific biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 23 Asia Pacific biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 24 Asia Pacific biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 25 Asia Pacific biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 26 China biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 27 China biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 28 China biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 29 Japan biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 30 Japan biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 31 Japan biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 32 India biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 33 India biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 34 India biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 35 South Korea biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 36 South Korea biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 37 South Koreabiomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 38 Australia biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 39 Australia biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 40 Australia biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 41 Latin America biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 42 Latin America biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 43 Latin America biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 44 Latin America biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 45 Brazil biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 46 Brazil biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 47 Brazil biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 48 Mexico biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 49 Mexico biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 50 Mexico biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 51 Argentina biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 52 Argentina biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 53 Argentina biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 41 MEA biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 42 MEA biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 43 MEA biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 44 MEA biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 45 South Africa biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 46 South Africa biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 47 South Africa biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 48 Saudi Arabia biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 49 Saudi Arabia biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 50 Saudi Arabia biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 51 UAE biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 52 UAE biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 53 UAE biomarkers market, by disease, 2014 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Value chain based sizing & forecasting
  • FIG. 4 QFD modeling for market share assessment
  • FIG. 5 Market summary
  • FIG. 6 Market trends &outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 Penetration & growth prospect mapping
  • FIG. 11 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Biomarkers market type outlook key takeaways
  • FIG. 14 Biomarkers market: Type movement analysis
  • FIG. 15 Safety biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 16 Efficacy biomarkers market, 2014 - 2026 (USD Billion)
  • FIG. 17 Validation biomarkers market, 2014 - 2026 (USD Billion)
  • FIG. 18 Biomarkers market application outlook key takeaways
  • FIG. 19 Biomarkers market: Application movement analysis
  • FIG. 20 Diagnostics market, 2014 - 2026 (USD Million)
  • FIG. 21 Drug discovery & development market, 2014 - 2026 (USD Million)
  • FIG. 22 Personalized medicines market, 2014 - 2026 (USD Million)
  • FIG. 23 Biomarkers market disease outlook key takeaways
  • FIG. 24 Biomarkers market: Disease movement analysis
  • FIG. 25 Cancer market, 2014 - 2026 (USD Million)
  • FIG. 26 Cardiovascular market, 2014 - 2026 (USD Million)
  • FIG. 27 Neurology market, 2014 - 2026 (USD Million)
  • FIG. 28 Immunology market, 2014 - 2026 (USD Million)
  • FIG. 29 Others market, 2014 - 2026 (USD Million)
  • FIG. 30 Regional market place: Key takeaways
  • FIG. 31 Regional outlook, 2018 & 2026
  • FIG. 32 North America biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 33 U.S. biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 34 Canada biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 35 Europe biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 36 UK biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 37 Germany biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 38 France biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 39 Asia Pacific biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 40 Japan biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 41 China biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 42 India biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 43 Latin America biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 44 Brazil biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 45 Mexico biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 46 MEA biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 47 South Africa biomarkers market, 2014 - 2026 (USD Million)
Back to Top